Tags Archive Navigation
icon
-
Media ReleaseNovartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
-
StoryA partnership against epilepsy
-
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Featured NewsWorld Sight Day 2022: Raising awareness on the importance of eye health
-
Media ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
-
StorySickle cell screening urged for newborns in Africa
-
Media ReleaseNovartis announces partnership with the American Society of Hematology to fight sickle cell disease in Sub-Saharan Africa
-
Media ReleaseNovartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria
-
Media ReleaseNovartis and GSK announce collaboration to support scientific research into genetic diversity in Africa
-
Media ReleaseNovartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
-
Media ReleaseNovartis reaches milestone delivery of 1 billion courses of antimalarial treatment
-
Media ReleaseNovartis global survey uncovers profound and often under-reported effects on sickle cell disease patients